Sunday, November 15, 2026

GBP/EUR Bearish Momentum: 0.97% Down In The Last 10 Sessions

ViaNews Editorial Team

September 28, 2023

Automated market report from our archive (2020-2024), published before source-traceability. How we work

GBP/EUR Bearish Momentum: 0.97% Down In The Last 10 Sessions

(VIANEWS) - GBP/EUR (GBPEUR) has been up by 0.97% for the last 10 sessions. At 11:08 EST on Thursday, 28 September, GBP/EUR (GBPEUR) is $1.15.

GBP/EUR's yearly highs and lows, it's 3.682% up from its 52-week low and 1.911% down from its 52-week high.

Volatility

GBP/EUR's last week, last month's, and last quarter's current intraday variation average was a negative 0.12%, a negative 0.06%, and a positive 0.26%, respectively.

GBP/EUR's highest amplitude of average volatility was 0.43% (last week), 0.26% (last month), and 0.26% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GBP/EUR's Forex is considered to be oversold (<=20).

News about

  • According to FXStreet on Tuesday, 26 September, "On the downside, EUR/USD faces immediate support at the March 15 low of 1.0516, followed by the 2023 low of 1.0481 seen on January 6.", "The selling pressure around EUR/USD remains everything but abated for yet another session, leaving the door wide open to further retracement in the short-term horizon."
  • Eur/usd could sink into the 1.0480/1.0510 support area: ING. According to FXStreet on Tuesday, 26 September, "Without support from extreme under-valuation or existing heavy short positioning, the EUR/USD pair looks as though it could sink into the 1.0480/1.0510 support area."
  • Eur/usd forex signal: euro stung by rising US bond yields - 26 September 2023. According to DailyForex on Tuesday, 26 September, "The EUR/USD exchange rate continued its brutal sell-off as the fear of soaring interest rates led to a major bond sell-off. ", "Forex Brokers We Recommend in Your Region See full brokers list 1 Read full review Get Started BrokerGeoLists.push({type:'ReviewsNonPartner',id:'horizontal-top-5',size:5,fullReviewText:`Read full review`,getStartedText:`Get Started`,readReviewText:`Review`});Bearish viewSell the EUR/USD pair and set a take-profit at 1.0545."
  • Eur/usd technical analysis: new support break - 26 September 2023. According to DailyForex on Tuesday, 26 September, "The EUR/USD exchange rate remains vulnerable to further losses and looks set to take another step towards the key support level of 1.05 in the coming days. ", "Expectations of the euro against the dollar today:According to the performance on today's chart below, the general trend of the EUR/USD currency pair is downward."
  • According to FXStreet on Tuesday, 26 September, "At the time of writing, EUR/USD is flirting with 1.0600 on its road to recovery. "

More news about GBP/EUR (GBPEUR).

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source, and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,580 source documents archived
Query this data → isubstrate.com